Human kidney microsomes and liver S9 fraction are most effective for in vitro metabolism studies of GHRPs and TB-500
Background
The use of small peptides (<2kDa) as performance-enhancing substances in sports is a growing concern for anti-doping agencies. Many of these compounds, such as Growth Hormone Releasing Peptides (GHRPs) and TB-500, are not approved for human use, making in vivo metabolism studies with human volunteers ethically and practically impossible. To detect their use, it's crucial to understand how they are broken down in the body and to identify their metabolites. This necessitates the development of reliable in vitro models that can accurately simulate human metabolism without requiring human trials. The challenge is to find a model that is both comprehensive and predictive of the complex enzymatic processes that occur in the human body.
Study Design
This study compared various in vitro model systems to investigate the biotransformation of several synthetic peptides, including GHRPs and TB-500. The researchers incubated these peptides with different biological preparations: commercially available proteases, human blood serum, human liver microsomes (HLM), human kidney microsomes (HKM), and human liver S9 fraction. The goal was to identify which system produced the most diverse and relevant pattern of metabolites, thereby determining the most efficient model for anti-doping metabolism research.
Results
The study found that different in vitro systems varied significantly in their metabolic activity. Human kidney microsomes (HKM) and the liver S9 fraction demonstrated the highest metabolic activity against GHRPs and TB-500. These two systems were capable of cleaving all peptide bonds, even in peptides with protective modifications in their primary structure.
Notably, both HKM and liver S9 fraction showed enzymatic deamidation activity, successfully removing the C-terminal amide group from all tested GHRPs.
In contrast, incubation with human serum produced fewer metabolites, indicating lower metabolic activity. The metabolite pattern generated by commercially available proteases was described as poor and consisted of non-specific hydrolyzed compounds. The maximum diversity of metabolites, which is crucial for identifying biomarkers for doping tests, was achieved using HKM and the liver S9 fraction.
Key Findings
- Human kidney microsomes (HKM) and liver S9 fraction showed the highest metabolic activity for GHRPs and TB-500.
- HKM and liver S9 fraction were capable of cleaving all peptide bonds, regardless of protective modifications.
- Both HKM and liver S9 demonstrated enzymatic deamidation, removing the C-terminal amide from all GHRPs.
- Incubation with human serum resulted in the production of fewer metabolites compared to HKM and liver S9.
- Commercially available proteases produced a poor and non-specific pattern of hydrolyzed metabolites.
Why It Matters
This research provides a clear roadmap for anti-doping laboratories on how to effectively study the metabolism of unapproved peptides. By identifying human kidney microsomes and liver S9 fractions as the most effective models, scientists can generate a comprehensive library of potential metabolites for compounds like GHRPs and TB-500. This is a critical step in developing sensitive and specific detection methods. For individuals using these peptides, it means that even if a parent compound is cleared quickly, a wider range of its metabolic byproducts can now be more easily identified, potentially extending the detection window. This work directly improves the ability to enforce anti-doping rules without relying on difficult-to-conduct human studies, making the testing process more robust and scientifically grounded.
TitrateLab articles covering TB-500
Written by TitrateLab, separately from the study summarized above.
